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Abstract
Cell sources and tissue integration between cartilage and bone regions are critical to successful
osteochondral regeneration. In this study, human umbilical cord mesenchymal stromal cells
(hUCMSCs), derived from Wharton’s jelly, were introduced to the field of osteochondral tissue
engineering and a new strategy for osteochondral integration was developed by sandwiching a
layer of cells between chondrogenic and osteogenic constructs before suturing them together.
Specifically, hUCMSCs were cultured in biodegradable poly-L-lactic acid scaffolds for 3 weeks in
either chondrogenic or osteogenic medium to differentiate cells toward cartilage or bone lineages,
respectively. A highly concentrated cell solution containing undifferentiated hUCMSCs was
pasted onto the surface of the bone layer at week 3 and the two layers were then sutured together
to form an osteochondral composite for another 3 week culture period. Chondrogenic and
osteogenic differentiation was initiated during the first 3 weeks, as evidenced by the expression of
type II collagen and runt-related transcription factor 2 genes, respectively, and continued with the
increase of extracellular matrix during the last 3 weeks. Histological and immunohistochemical
staining, such as for glycosaminoglycans, type I collagen and calcium, revealed better integration
and transition of these matrices between two layers in the composite group containing sandwiched
cells compared to other control composites. These results suggest that hUCMSCs may be a
suitable cell source for osteochondral regeneration, and the strategy of sandwiching cells between
two layers may facilitate scaffold and tissue integration.
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1. Introduction
Osteochondral tissue engineering has been proposed as a potential cure for both
osteochondral and cartilage defects. The damage of two distinct tissues, bone and cartilage,
in osteochondral defects necessitates the regeneration of integrated complex tissues. More
recently, osteochondral strategies have been advocated for cartilage repair instead of solely
cartilage engineering, due to the difficulty of integrating engineered constructs with the
cartilage surrounding the excised cartilage. In contrast, the integration of bone-to-bone
fusion is far superior to cartilage-to-cartilage fusion because of the well-known healing
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ability of bone tissues (Grayson et al., 2008). Although osteochondral constructs have been
engineered using a variety of biomaterials with different types of cells, the choice of cell
sources and osteochondral integration are still major issues for osteochondral tissue
engineering.
For a successful osteochondral strategy, it is necessary to adopt a cell source that must be
easily isolated and quickly expanded to obtain sufficient cell numbers, has low immune
response, and ideally has no donor site morbidity. Mature autologous chondrocytes and
osteoblasts are limited by their proliferation ability in vitro and donor site morbidity. Stem
cells, such as bone marrow cells and adipose stem cells, offer a feasible alternative to
differentiated autologous cells, with the potential to undergo continuous self-renewal and
differentiate toward osteogenic and chondrogenic lineages. Recently, human umbilical cord
mesenchymal stromal cells (hUCMSCs), derived from the Wharton’s jelly of umbilical
cords, have been introduced to both cartilage and bone tissue engineering with many
advantages over other adult cell sources (Bailey et al., 2007; Wang et al., 2009a, 2009b,
2009c). hUCMSCs are an inexhaustible stem cell source, are easy to isolate without ethical
controversies and invasive procedures, are quickly expanded and thus far appear to exhibit a
low immune-rejection reaction in vivo (Wang et al., 2004; Sarugaser et al., 2005; Fu et al.,
2006; Weiss and Troyer, 2006; Karahuseyinoglu et al., 2007), thus providing an excellent
option as a stem cell source for osteochondral tissue engineering. A variety of biomaterials,
both natural and synthetic, have been developed for bone and cartilage tissue engineering
applications (Ishaug-Riley et al., 1999; Stevens et al., 2004; Richardson et al., 2006;
Zwingmann et al., 2007). In this study, poly-L-lactic acid (PLLA) was chosen for the
scaffolds, mainly due to its relatively slow degradation rate and excellent biocompatibility.
In a previous study (Wang et al., 2009b), hUCMSCs differentiated into osteoblast-like cells
in PLLA scaffolds and the scaffolds maintained their original shape during a 6 week in vitro
culture period. Therefore, in the current study, hUCMSCs were seeded into PLLA scaffolds
separately for osteogenic and chondrogenic differentiation, followed by scaffold integration
using a suturing method.
An ideal structure of osteochondral constructs should mimic native osteochondral joints,
which possess a seamless transition between bone and cartilage. A traditional way to
achieve this goal is to fabricate biphasic composites that have two independent layers to
meet the different demands of bone and cartilage regeneration and then integrate them by
various techniques, including layering of cartilage- and bone-like regions (Cao et al., 2003;
Alhadlaq and Mao, 2003, 2005; Alhadlaq et al., 2004; Malafaya and Reis, 2009; Guo et al.,
2009, 2010), painting chondrocytes onto an osteoblast-containing construct (Weng et al.,
2001), suturing (Schaefer et al., 2000; Mrosek et al., 2010) or press-fitting (Schaefer et al.,
2002; Tuli et al., 2004) the two layers together, use of a fibrin sealant (Gao et al., 2001) to
adhere the two, and simply relying on in vivo conditions (Wakitani et al., 1994; Angele et
al., 1999). However, these methods did not necessarily lead to solid integration and smooth
transition between two layers, possibly due to sparse cells on the interface, consequently
resulting in the separation of bone and cartilage (O’Shea and Miao, 2008). In the current
study, we proposed a new integration strategy by sandwiching a layer of highly concentrated
cell suspension between two layers of cell-seeded PLLA scaffolds, and then suturing the two
constructs together, and hypothesized that this cell layer would promote better integration
and transition from the cartilage-like to bone-like layers than only suturing two tissues
without sandwiched cells. The integration of cartilage and bone layers was assessed by
histology and immunohistochemistry and the differentiation of hUCMSCs was examined by
gene expression and extracellular matrix (ECM) levels over a 6 week culture period.
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2. Materials and methods
2.1. Isolation of hUCMSCs
Four cords (three males and one female, 20 ± 5 cm in length) were obtained from four
patients at the University of Kansas (KU) Medical Center with IRB approvals (KU-
Lawrence No. 15 402 and KU Medical Center No. 10 951) and were processed within 24 h
following a previous method (Wang et al., 2009a). After cell isolation, hUCMSCs were
recorded as passage 1 (P1) and plated at 6000 cells/cm2 in cell culture flasks in a complete
culture medium consisting of low-glucose Dulbecco’s modified Eagle’s medium (DMEM-
LG; Invitrogen, Carlsbad, CA, USA), 10% MSC-qualified fetal bovine serum (FBS;
Invitrogen) and 1% penicillin/streptomycin (PS; Invitrogen). P4 hUCMSCs were used for
the following experiments.
2.2. Surface antigens of hUCMSCs
P4 hUCMSCs were characterized by flow cytometry to analyse specific surface antigens of
the mesenchymal cell lineage, including CD29, CD49e, CD73, CD90 and CD105. All
supplies were purchased from BD Biosciences (San Jose, CA, USA) except CD73 and
CD105 from eBioscience (San Diego, CA, USA). Approximately 0.5 × 106 cells/vial were
used for each antigen. Non-specific binding was first blocked with a staining buffer
containing 2% FBS in PBS for 15 min and the cells were then incubated with single-label
antigen for 20 min on ice. Mouse isotype antigens served as a negative control. Flow
cytometry analysis was conducted using a FACscan flow cytometer (BD Biosciences).
2.3. Seeding hUCMSCs into PLLA scaffold
Non-woven PLLA meshes (50 mg/cc, >95% porosity; Biomedical Structures LLC, RI,
USA) were punched into cylindrical scaffolds (5 mm diameter, 2 mm thickness). Scaffolds
were sterilized using an ethylene oxide chamber following a previous procedure (Wang et
al., 2009a). 0.98 × 106 hUCMSCs in 35 μl of the complete medium were seeded in a
dropwise manner into each scaffold to achieve a cell density of 25 × 106 cells/ml of scaffold.
Cell-seeded scaffolds were incubated in a cell culture incubator for 3 h to allow for cell
attachment. To keep the constructs hydrated, 10 μl complete medium was added every 1 h.
After the 3 h period, 2 ml of either chondrogenic or osteogenic medium was added into each
culture well. Chondrogenic medium consisted of high-glucose DMEM (DMEM-HG;
Invitrogen), 1% non-essential amino acids (NEAA; Invitrogen), 1× sodium pyruvate
(Invitrogen), 1× insulin transferring selenium premix (ITS premix; BD Biosciences), 50 μg/
ml ascorbic acid 2-phosphate (AA2P; Sigma, St Louis, MO, USA), 40 μg/ml L-proline
(Sigma), 100 nM dexamethasone (Sigma) and 10 ng/ml transforming growth factor beta-1
(TGFβ1; R&D Systems, NJ, USA). Osteogenic differentiation medium consisted of the
complete culture medium supplemented with 100 nM dexamethasone, 10 mM β-
glycerophosphate (β-GP; Sigma), 50 μg/ml AA2P and 10 nM 1α,25-dihydroxyvitamin D3
(BIOMOL International, Plymouth Meeting, PA, USA). The media were changed every 2
days for 3 weeks before scaffold integration.
2.4. Fabrication of osteochondral composites
After 3 weeks of culture, two PLLA constructs were sutured together using surgical suture
needles and a 3-0 silk suture to create osteochondral composites. Four different composite
groups were designed: (a) two chondrogenic constructs (C–C); (2) two osteogenic constructs
(O–O); (3) chondrogenic and osteogenic constructs (C–O); (4) chondrogenic and osteogenic
constructs with a layer of undifferentiated hUCMSCs solution sandwiched between two
layers (C–cell–O). In the group of C–cell–O composites, 10 μl 100 × 106/ml hUCMSCs
solution was painted onto the surfaces of the osteogenic constructs using a micropipette, and
Wang et al. Page 3













chondrogenic and osteogenic constructs were then sutured together with the painted surface
toward the chondrogenic constructs. All composites were cultured in a composite culture
medium consisting of DMEM-LG, 2% FBS, 1% PS, 1× sodium pyruvate, 1× ITS, 5 mM β-
GP, 50 μg/ml AA2P, 100 nM dexamethasone, 40 μg/ml L-proline and 100 ng/ml insulin-like
growth factor-I (IGF-I; PeproTech, Rocky Hill, NJ, USA). IGF-I was chosen for its anabolic
capacity in both osteogenesis and chondrogenesis (Kasukawa et al., 2004; Wang and
Detamore, 2009). The medium was changed every 2 days for a 3 week period; therefore, the
total period of this study was 6 weeks. At week 6, osteochondral composites, including C–C,
O–O, C–O and C–cell–O, were separated into two parts. After separation, both C–C and O–
O composite became two parts and only one of them was randomly selected for analysis.
Both C–O and C–cell–O composites became two different parts, osteogenic and
chondrogenic, and both of them were used for the assays.
2.5. Biochemical assays
Biochemical assays (n = 4) included the quantification of DNA, glycosaminoglycans
(GAGs), hydroxyproline (HYP) and calcium deposition at weeks 0, 3 and 6. To measure
DNA, GAG and HYP contents, the samples were digested in 1.5 ml 120 μg/ml papain
solution at 60 °C overnight. DNA and GAG contents were determined using a PicoGreen kit
(Invitrogen) and a dimethylmethylene blue (DMMB) dye binding assay (Biocolor, Belfast,
UK), following the manufacturers’ respective procedures. HYP contents were determined
using a HYP assay protocol described in the literature (Wang et al., 2009a). To measure
calcium contents, samples were digested in 1 N acetic acid overnight at room temperature.
Calcium content was measured using an ortho-cresolphthalein complexone (OCPC) method
(ter Brugge and Jansen, 2002). 10 μl digestion solution and 300 μl assay reagent were mixed
and incubated for 10 min at room temperature and then read at 575 nm.
2.6. Immunohistochemistry and histology
Constructs were frozen in an optimal cutting temperature (OCT) medium (Sakura Finetek;
Torrance, CA, USA) and sectioned at a thickness of 10 μm using a cryostat (Microm;
Thermo Scientific, Waltham, MA, USA). Types I and II collagen and aggrecan were
examined immunohistochemically, using a BioGenex i6000 autostainer (BioGenex, San
Ramon, CA, USA) as described previously (Detamore and Athanasiou, 2005; Detamore et
al., 2005). Primary antibodies included the mouse monoclonal IgG anti-collagen I (1 : 1500
dilution; Accurate Chemical and Scientific, Westbury, NY, USA), mouse monoclonal IgG
anti-collagen II (1 : 1000 dilution; Chondrex, Redmond, WA, USA) and mouse monoclonal
IgG anti-aggrecan (1 : 50 dilution; Abcam, Cambridge, MA, USA). In brief, endogenous
peroxidase activity was inhibited using 1% hydrogen peroxide, blocked in horse serum and
incubated with primary antibodies. Following the incubation, the sections were then
incubated with a streptavidin-linked horse anti-mouse IgG secondary antibody (Vector
Laboratories, Burlingame, CA, USA). After the incubation with secondary antibodies, the
sections were incubated with an avidin–biotinylated enzyme complex (ABC Complex;
Vector Laboratories) and were finally stained with VIP substrate (purple colour; Vector
Laboratories) and counterstained with Harris haematoxylin (blue colour; Fisher Scientific,
PA, USA). Histological analyses were performed to visualize the distribution of GAGs and
cells using safranin O/fast green staining and to detect calcium minerals using alizarin red
staining.
2.7. Real-time reverse transcription polymerase chain reaction (RT–PCR)
Total RNA was extracted with TRIzol reagents (Invitrogen) and mRNA was reverse-
transcribed to cDNA using a High-Capacity cDNA Archive Kit (Applied Biosystems, Foster
City, CA, USA). Quantitative PCR reactions were performed in an Applied Biosystems
7500 Fast System. TaqMan gene expression assay kits (Applied Biosystems) were used to
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measure the transcript levels of genes, including collagen I (Hs00164004_m1), collagen II
(Hs00156568_m1), aggrecan (Hs00153936_m1), osterix (OSX; Hs00541729_m1), runt-
related transcription factor 2 (RUNX2; Hs00231692_m1), osteocalcin (OCN;
Hs01587813_g1), bone sialoprotein (BSP; Hs00173720_m1), and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH; Hs99999905_m1). All genes were tested with the
constructs at weeks 0 and 3 and with the C–C and O–O composites at week 6. The
chondrogenic parts of the C–O and C–cell–O composites were used to detect types I and II
collagen, and aggrecan genes and their osteogenic parts were used to detect the osteogenic
genes, including RUNX2, OSX, OCN and BSP. The relative expression level for each target
gene was evaluated using the 2−ΔΔCt method (Livak and Schmittgen, 2001).
2.8. Data analysis
All data were expressed as means ± standard deviation (SD) and analysed by analysis of
variance (ANOVA) followed by Tukey’s honestly significant difference (HSD) post hoc
tests. A statistical threshold of p < 0.05 was used to detect whether there were statistical
significances among different groups.
3. Results
3.1. Surface antigens of hUCMSCs
Passage 4 hUCMSCs were characterized by surface antigen expression using flow
cytometry (Figure 1). hUCMSCs expressed high levels of matrix markers, including CD44
(97.3%) and CD105 (97.5%), integrin markers CD29 (98.0%) and MSC markers, including
CD49e (96.5%), CD73 (95.2%) and CD90 (98.8%), while hUCMSCs were negative to
haematopoietic markers including CD34 (<1%) and CD45 (<1%).
3.2. DNA contents
In general, DNA contents in the chondrogenic groups decreased over the 6 week period (p <
0.05) (Figure 2a). Specifically, the DNA content decreased by 40% in the chondrogenic
constructs from weeks 0 to 3 (p < 0.05) and was maintained from weeks 3 and 6 (p > 0.05).
At week 6, the chondrogenic part of the C–cell–O composite had a similar DNA content to
the DNA content at week 3, while it had 1.3 and 1.4 times higher DNA contents than the C–
C composites (p > 0.05) and the chondrogenic parts of C–O composites (p < 0.05) at week
6, respectively. The DNA content was maintained in osteogenic constructs during the first 3
week period and decreased by 23% from weeks 3 to 6 in the O–O composites and the
osteogenic parts of C–O composites (p < 0.05). The osteogenic parts of the C–cell–O
composites had a comparable DNA content to the osteogenic constructs at week 3 (p > 0.05)
and had 1.3 times higher DNA contents than the O–O composites and the osteogenic parts
of C–O composites (p < 0.05) at week 6. With regard to the comparison between
chondrogenic and osteogenic groups, all osteogenic groups had a higher DNA content than
chondrogenic groups at both weeks 3 and 6 (p < 0.05). There was 1.6 times more DNA in
the osteogenic constructs than in the chondrogenic constructs at week 3 (p < 0.05). At week
6, the DNA content in the O–O composites was 1.5 times higher than in the C–C composites
(p < 0.05). The osteogenic parts of both C–O and C–cell–O composites had 1.6 times more
DNA than their chondrogenic parts (p < 0.05).
3.3. GAG content
GAG contents increased markedly in the chondrogenic groups in the first 3 weeks, with 2.7
times higher values at week 3 than at week 0 (p < 0.05) and were maintained from weeks 3
to 6 (p > 0.05) (Figure 2b). There was no significant difference in GAG contents among all
chondrogenic groups at week 6. All osteogenic groups had similar GAG contents to each
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other over 6 weeks, although there was a slight drop from weeks 3 to 6 in all composites (p
> 0.05). In comparison to the osteogenic groups, the GAG contents in the chondrogenic
groups were significantly higher at both weeks 3 and 6 (p < 0.05). The chondrogenic
constructs had 2.3 times more GAGs than the osteogenic constructs at week 3 (p < 0.05). At
week 6, the C–C composites had 2.4 times more GAGs than the O–O composites (p < 0.05).
The GAG contents in the chondrogenic parts of both the C–O and C–cell–O composites
were 2.7 times higher than their osteogenic parts (p < 0.05).
3.4. Hydroxyproline (HYP) contents
In the chondrogenic groups, HYP contents increased continuously from week 0 to 6 (p <
0.05) (Figure 2c). The highest HYP production was observed in the C–C composites at week
6 with 156 and 2.6 times more HYP than the chondrogenic constructs at weeks 0 and 3,
respectively (p < 0.05). At week 6, the C–C composites also had 1.6 and 1.3 times more
HYP than the chondrogenic parts of the C–O and C–cell–O groups (p < 0.05), respectively,
while there was no significant difference between the C–O and C–cell–O composites. Like
the chondrogenic groups, the osteogenic groups also had an increased HYP content
throughout the 6 week culture period (p < 0.05), whereas no significant differences were
discerned among all groups at week 6. With regard to the comparison between the
chondrogenic and osteogenic groups, the chondrogenic groups had significantly higher HYP
contents than the osteogenic groups over 6 weeks (p < 0.05). At week 3, the chondrogenic
constructs had 4.6 times more HYP than the osteogenic constructs. At week 6, the C–C
composites had 4.9 times more HYP than the O–O composites (p < 0.05). HYP contents in
the chondrogenic parts of the C–O and C–cell–O composites were 3.1 and 3.5 times higher
than in their osteogenic parts, respectively (p < 0.05).
3.5. Calcium contents
Calcium contents in the chondrogenic groups slightly increased from weeks 0 to 6, but
without significant differences (Figure 2d). In contrast, calcium contents drastically
increased over time in the osteogenic groups (p < 0.05). At week 6, the O–O composites had
the highest calcium contents among all composites, with 1.5 and 2.1 times more calcium
than the osteogenic parts of the C–O and C–cell–O groups, respectively (p < 0.05).
Compared to calcium contents in the chondrogenic groups, which were <1 μg/μg DNA, all
osteogenic groups had higher calcium deposition, in the range 2.4–9.4 μg/μg DNA over the
6 week period (p < 0.05).
3.6. Histology and immunohistochemistry
Chondrogenic and osteogenic potentials of hUCMSCs and scaffold integration at the
interface between the chondrogenic and osteogenic parts of all composites were evaluated
by histology and immunohistochemistry. At week 3 (Figure 3), the chondrogenic constructs
had weak staining for type I collagen and aggrecan by immunohistochemistry, and moderate
staining of GAGs by safranin-O staining, while no positive staining was observed in type II
collagen immunohistochemical staining and alizarin red staining for calcium deposition. In
contrast, in the osteogenic constructs, calcium deposition and type II collagen were observed
in the peripheral region of the constructs, while there was no positive staining for type I
collagen, aggrecan and GAGs.
At week 6 (Figure 4), all stainings presented a more homogeneous cell and matrix
distribution in the chondrogenic groups than in the osteogenic groups. Cells and ECM were
mainly located at the peripheral area in the osteogenic groups. Regarding the scaffold
integration at week 6, all stainings revealed that the C–cell–O composite exhibited the best
integration and transition of ECM between two layers among all composites. The C–O
composites also had a good integration in the middle of the interface, while the edge of the
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interface was absent of cells and ECMs and formed large V-shaped dents. Another
noticeable difference between the C–cell–O and C–O composites was the distribution and
amount of calcium deposition, type II collagen and aggrecan. In the C–cell–O composites at
week 6, calcium was distributed only on the surface exposed to the cell culture medium and
there were no calcium on the surface facing the osteochondral interface, although calcium
was deposited around the surface of osteogenic constructs at week 3. In the C–O
composites, calcium was distributed on all surfaces of the osteogenic parts and led to a sharp
transition of calcium from chondrogenic to osteogenic parts at week 6. Moreover, the C–O
composites had stronger staining of calcium in the osteogenic parts, and stronger type II
collagen and aggrecan staining in the chondrogenic parts, than in the C–cell–O composites.
With regard to the C–C and O–O composites, there was a strong positive staining of type I
collagen, a weak staining of aggrecan and a trace staining of type II collagen in the C–C
composites by immunohistochemistry, and histology revealed no GAG staining and no
calcium deposition. In contrast, the O–O composites had a stronger calcium staining and a
more intense type I collagen staining on the borders. The C–C composites also had dents
similar to the C–O composites at the edge with homogeneous ECM distribution at week 6,
while the O–O composites presented an obvious discontinuity of all types of stainings
between the two parts.
3.7. Gene expression
At weeks 3 and 6, chondrogenic genes, including type II collagen and aggrecan, increased
significantly in the chondrogenic groups (p < 0.05), while these genes did not appear in the
osteogenic groups at week 3 and the O–O composites at week 6 (Figure 5a). The expression
of type I collagen genes was upregulated in all tested groups (p < 0.05) (Figure 5a). The
RUNX2 gene in osteogenic constructs increased by 20-fold during weeks 0–3 (p < 0.05) and
remained at a high level during weeks 3–6, while other osteogenic genes, including OSX,
OCN and BSP, did not have significant increases during the 6-week culture (p > 0.05). None
of the osteogenic genes in the chondrogenic constructs at week 3 and the C–C composites at
week 6 significantly increased over 6 weeks.
4. Discussion and conclusion
The aim of this study was to investigate the feasibility of fabricating an integrated
osteochondral construct using hUCMSCs and an integration strategy of sandwiching cells
between two layers. As a fetus-derived stem cell source, hUCMSCs have various benefits
over adult stem cell sources, such as faster proliferation, non-invasive collection and ample
availability. Here, we applied hUCMSCs to osteochondral tissue engineering in a composite
approach. Chondrogenic and osteogenic differentiation was observed in the first 3 weeks, as
evidenced by the expression of type II collagen and RUNX2 genes, respectively, and
continued with the increase of extracellular matrix during the last 3 weeks. To promote the
integration and transition on the osteochondral interface, we introduced the approach of
sandwiching a layer of undifferentiated hUCMSCs between chondrogenic and osteogenic
constructs and hypothesized that this cell layer would help to develop a more well-integrated
transition between them. Indeed, we observed the best integration in the C–cell–O group
among all groups by immunohistochemistry and histology.
All chondrogenic groups not only appeared cartilaginous by immunohistochemical and
histological observation but were quantitatively characterized by rich ECM, including GAG
and HYP production. Immunohistochemical analysis showed a small amount of type II
collagen and aggrecan and an abundant amount of type I collagen in the chondrogenic
groups. Histological analysis showed rich staining for GAGs in the chondrogenic groups at
week 3, although these GAGs did not aggregate to form a large amount of aggrecan, as
indicated by only a weak aggrecan staining. RT–PCR analysis also revealed the upregulation
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of cartilage-specific genes, including type II collagen and aggrecan. These data collectively
indicated that hUCMSCs progressed toward a chondrogenic lineage in 3D PLLA scaffolds.
However, it must be noted that the matrix was more fibrous in nature due to the existence of
a large amount of type I collagen. Exposed to osteogenic signals, hUCMSCs differentiated
toward an osteogenic lineage, as evidenced by calcium deposition and the upregulation of
RUNX2 gene expression in the first 3 weeks. During this period, the distribution of type II
collagen around the periphery of the osteogenic groups, which diminished with time, may
have indicated a transient heterogeneity of UCMSCs at week 3. The RUNX2 gene
expression was maintained in the osteogenic groups during the subsequent culture, while
calcium contents continued to increase over time. Despite this evidence for early-stage
osteogenic differentiation, the low levels of the other osteogenic genes, including BSP, OSX
and OCN, may indicate that the mature osteoblast stage was not reached within 6 weeks,
necessitating future optimization of differentiation conditions and/or a longer differentiation
period.
In composite culture medium from weeks 3 to 6, the cells in the C–C composites and the
chondrogenic parts of the C–O and C–cell–O composites did not appear to be undergoing
osteogenic differentiation, although the composite media included supplements such as
dexamethasone and β-glycerophosphate, which suggests the possibility that the hUCMSCs
may have lost their ‘stemness’ and differentiated toward chondrocyte-like cells in the first 3
weeks chondrogenic exposure. However, we did observe the disappearance of GAGs at
week 6, revealed by negative safranin O staining, probably due to the absence of
chondrogenic signals in the composite media. Furthermore, the cells in the O–O composites
and the osteogenic parts of the C–O and C–cell–O composites did not undergo chondrogenic
differentiation, to which some of the following reasons may contribute. First, hUCMSCs
may differentiate toward osteoblast-like cells during the first 3 weeks. Second, at week 6,
the composite media included the osteogenic supplements, dexamethasone and β-
glycerophosphate, while excluding chondrogenic signals, TGFβ1. Based on DNA content,
the cell number appeared to decrease with culture time in both osteogenic and chondrogenic
groups. This drop in cell number is a common theme we have observed with non-woven
PLLA (Wang et al., 2009b) and also with PGA scaffolds (Wang et al., 2009c). One possible
reason for the loss of cells could be that the cells were seeded at a high seeding density,
which may limit cell proliferation; also, dexamethasone, an inhibitor of cell proliferation,
existed in all types of media used in this study. Moreover, it appears that cell adhesion
suffers on these types of scaffolds without some type of adhesion moiety. At week 6, we
observed more cells in the C–cell–O composites than in other composites, a lower HYP
content per DNA in the C–cell–O composites than in the C–C composites, and a lower
calcium content per DNA in the C–cell–O composites than in the O–O composites. There
are two factors contributing to these differences. First, a higher cell number in C–cell–O
composites was partly due to the addition of sandwiched cells, while similar HYP and
calcium contents per construct were detected between the C–cell–O composites and the C–C
and O–O composites, thus resulting in a lower HYP and calcium per DNA than in the C–C
and O–O composites. Second, endogenous chemical signals released by cells in
chondrogenic, osteogenic or sandwiched layers into the media may have affected cell
proliferation and ECM synthesis in the opposite layer.
In osteochondral tissue engineering, a major challenge is to integrate chondrogenic and
osteogenic regions seamlessly. For this purpose, various methods have been adopted in
previous studies (Wakitani et al., 1994; Angele et al., 1999; Schaefer et al., 2000, 2002; Gao
et al., 2001; Weng et al., 2001; Cao et al., 2003; Alhadlaq and Mao, 2003, 2005; Alhadlaq et
al., 2004; Tuli et al., 2004; Malafaya and Reis, 2009; Guo et al., 2009, 2010; Mrosek et al.,
2010). In our study, better integration was achieved at the interface between chondrogenic
and osteogenic parts when we included a layer of undifferentiated cells in between. After 6
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weeks of culture, there appeared to be a higher cell number with intensive ECM staining at
the interface of C–cell–O composites, indicated by positive immunohistochemical and
histological staining. These ECMs on the interface served as a filler to fill the gaps caused
by the simple suturing techniques in the other groups and may have acted as a biological
glue to bridge the chondrogenic and osteogenic parts, thus resulting in better integration
between constructs. Compared to the existence and sharp transition of calcium on the
interface in the C–O composite, calcium deposition gradually disappeared across the
interface in the C–cell–O composite at week 6, leading to a better transition between
scaffolds and also indicating that the sandwiched cells may affect the calcium remodelling
directly or indirectly. The sandwiched cells seem to affect chondrogenic differentiation in
the chondrogenic parts of the C–cell–O composites, as we observed weaker staining of type
II collagen and aggrecan. To further track sandwiched cells and associated gene expression,
fluorescent tracking techniques for cells can be used to investigate cell viability and
migration, and gene expression of these cells can also be achieved by in situ hybridization.
Immunohistochemical and histological staining also revealed a more homogeneous
distribution of cells and ECM inside chondrogenic constructs than in osteogenic constructs
at weeks 3 and 6. The different nature of chondrocyte-like and osteoblast-like cells may
have contributed to this difference. Compared to chondrocytes, osteoblasts reside in an
environment abundant in oxygen and nutrients, due to the existence of blood vessels,
indicating that osteoblasts may have higher demands for oxygen and nutrients and thus may
migrate toward the peripheral area of constructs. Moreover, it is surprising that we observed
a clear discontinuity in the O–O composite and a better fusion in the C–C composites,
because one of the motivations of using osteochondral composites is to take advantage of a
better ability to fuse a bone-to-bone interface than a cartilage-to-cartilage interface. The
absence of blood vessels in vitro may contribute to this discrepancy.
In conclusion, a novel osteochondral construct was fabricated using hUCMSCs as an
alternative to mature cells and other stem cells. hUCMSCs allowed the fabrication of
osteochondral constructs from a single cell source with the chondrogenic and osteogenic
potentials, as demonstrated here. A new integration strategy was developed by sandwiching
undifferentiated hUCMSCs between the chondrogenic and osteogenic parts before suturing
them. The connection of chondrogenic and osteogenic constructs was significantly improved
by the sandwiched cells and their ECM on the interface. Future experiments will be directed
toward both mechanical and biochemical evaluation of these constructs in vitro and in vitro
after a long-term culture and/or implantation for more than 6 weeks.
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Flow cytometry analysis of surface antigens on human umbilical cord mesenchymal cells
(hUCMSCs) (n = 4). hUCMSCs expressed a set of MSC markers and did not express
haematopoietic markers
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Biochemical analyses (mean ± SD, n = 4) for the individual chondrogenic and osteogenic
constructs at week 3 and for the chondrogenic and osteogenic parts of the composites at
week 6. At week 6, osteochondral composites, including C–C, O–O, C–O and C–cell–O,
were separated into two parts. In the C–C and O–O composites, only one part was used for
the assays. In the C–O and C–cell–O composites, both parts, osteogenic and chondrogenic,
were used separately for the assays: (a) DNA content; (b) normalized glycosaminoglycan
(GAG) content; (c) normalized hydroxyproline (HYP) content; and (d) normalized calcium
content. The chondrogenic constructs had lower DNA and calcium contents and higher
GAG and HYP contents than the osteogenic constructs at both weeks 3 and 6. The C–cell–O
composites had higher DNA contents than other composites at week 6. *, Statistically
significant difference between weeks 0 and 3; #, statistically significant difference between
weeks 3 and 6 among either chondrogenic or osteogenic groups; φ, statistically significant
difference between the C–O-cell composites and the C–O composites at week 6; &,
statistically significant difference from the other two groups in either chondrogenic or
osteogenic parts at week 6; @, statistically significant difference between chondrogenic and
osteogenic groups. Chondro, chondrogenic groups; osteo, osteogenic groups; C–C,
composite containing two chondrogenic constructs; O–O, composite containing two
osteogenic constructs; C–O, composite containing chondrogenic and osteogenic constructs;
C–cell–O, composite containing chondrogenic and osteogenic constructs with a layer of
undifferentiated hUCMSCs at the interface
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Immunohistochemical staining for types I and II collagen and aggrecan and histological
stainings including safranin-O staining for glycosaminoglycan (GAG) and alizarin red
staining for calcium at week 3 (n = 2). Moderate aggrecan and GAG stainings indicated
differentiation toward a chondrogenic lineage in chondrogenic constructs. A strong calcium
staining indicated differentiation toward an osteogenic lineage in osteogenic constructs.
Scale bar = 250 μm
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Immunohistochemical staining for types I and II collagen and aggrecan, and histological
stainings including safranin-O staining for glycosaminoglycans (GAGs) and alizarin red
staining for calcium at week 6 (n = 2). All stainings revealed better integration and transition
in C–cell–O groups than in the C–O groups. Scale bar = 500 μm
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Gene expression analysis (mean ± SD, n = 4). (a) Gene expression of types I and II collagen
(CI and CII) and aggrecan (AGC) with the constructs at week 0, chondrogenic (C) and
osteogenic (O) constructs at week 3, C–C and O–O composites at week 6, and the
chondrogenic part of the C–O and C–cell–O composites at week 6. (b) Gene expression of
runt-related transcription factor 2 (RUNX2), osterix (OSX), bone sialoprotein (BSP) and
osteocalcin (OCN) with the constructs at week 0, chondrogenic (C) and osteogenic (O)
constructs at week 3, C–C and O–O composites at week 6, and the osteogenic part of the C–
O and C–cell–O composites at week 6. The increase of CII and AGC gene expression
indicated chondrogenic differentiation of hUCMSCs (a) and the increase of RUNX2 gene
expression indicated osteogenic differentiation of hUCMSCs (b). *Statistically significant
difference from week 0
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